Genome-wide association studies have helped identify more than 90 loci that affect a person’s chance of getting Alzheimer’s disease, but these common variants still leave a portion of disease ...
As part of the mammalian innate immune response, the complement system evolved to fight off foreign microbes, and it also helps the brain stave off amyloid plaques. But are all proteins in this ...
When it comes to new brain anatomy, clearance pathways seem to be the gift that keeps on giving. In a preprint posted September 27 on bioRxiv, scientists led by David Attwell at University College ...
The approval of amyloid-targeted monoclonal antibodies as disease-modifying therapies was a landmark moment for the Alzheimer’s field, but risks and monitoring requirements hamper acceptance by ...
Can brain amyloid reduction be used as a surrogate biomarker of clinical benefit? This is a hotly debated question in the field (see Dec 2024 discussion). A recent post hoc analysis of Phase 3 ...
CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...
White-matter hyperintensities, a sign of damage to the brain’s vasculature, are common on MRI scans of people with Alzheimer’s disease. Do they indicate an independent vascular co-pathology, or are ...
Aβ may stimulate p-tau secretion at lipid rafts in the neuronal membrane. Plaque growth, not presence, pierces axonal membranes, releasing p-tau. Turning interneuron activity up or down modulates ...
Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...
Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...
More antibodies take aim at seeded propagation. New data ties tangle location to deficits in specific cognitive domains. Three first-in-human studies for antibodies targeting different parts of tau ...
On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results